Effect of telmisartan on blood pressure in patients of type 2 diabetes with or without complications

Gadge, Pradeep; Gadge, Roshani P.; Paralkar, Nikita D.; Jain, Preeti; Tanna, Vrunda

doi:10.4103/picr.picr_93_17

Cited by 6 publications

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, telmisartan had beneficial effects on other metabolic parameters; these included its effects on significantly lowering blood sugar levels and altering lipid profiles. Amlodipine, however, did not affect these metabolic parameters 24 . Moreover, studies have shown that combination therapy with amlodipine/telmisartan effectively lowers BP in individuals with uncontrolled hypertension who had previously been treated with ARB monotherapy 27 , 28 .…”

Section: Discussionmentioning

confidence: 73%

The Indian registry on current patient profiles & treatment trends in hypertension (RECORD): One year interim analysis

Rajadhyaksha,

Reddy,

Singh

et al. 2023

Indian Journal of Medical Research

View full text Add to dashboard Cite

Background & objectives: In India, hypertension constitutes a significant health burden. This observational, non-interventional, prospective study was conducted in five centres across India to evaluate the current clinical practices for the management of hypertension. Methods: Participants were enrolled if they were newly diagnosed with essential hypertension or had pre-existing hypertension and were on the same therapeutic plan for the previous three months. At baseline, three months, six months, and one year, information on the patient and their treatment regimen was documented, and their quality of life (QoL) was evaluated. Results: A total of 2000 individuals were enrolled in this study, with a mean age of 54.45 yr. Of these, 55.7 per cent (n=1114) were males, and 957 (47.85%) were newly diagnosed with hypertension, while 1043 (52.15%) had pre-existing hypertension. Stage 2 hypertension (systolic blood pressure (BP) >140 or diastolic BP ≥90 mmHg) accounted for more than 70 per cent of the participants (70.76% of pre-existing and 76.29% of newly diagnosed); the average duration of pre-existing hypertension was 68.72 months. Diabetes (31.6%) and dyslipidaemia (15.8%) were the most common comorbidities. In 43.3 per cent of the participants, monotherapy was used, and in 56.7 per cent (70.55% fixed-dose combination), combination therapy was used. Telmisartan (31.6%), amlodipine (35.2%), and a combination of the two (27.1%) were the most commonly prescribed treatment regimens. At three months, six months, and one year, treatment modifications were observed in 1.4, 1.05, and 0.23 per cent of the participants receiving monotherapy and 2.74, 4.78 and 0.35 per cent receiving combination therapy, respectively. In both groups, the proportion of individuals with controlled hypertension (≤140/90 mmHg) increased by more than 30 per cent after a year. At one year, physical and emotional role functioning, social functioning, and health improved considerably. Interpretation & conclusions: Combination therapy for hypertension is increasingly preferred at the time of initial diagnosis. The efficacy, safety, and tolerance of the recommended medications were reflected by improvements in the QoL and the minimal changes in the therapeutic strategy required.

show abstract

Section: Discussionmentioning

confidence: 73%

The Indian registry on current patient profiles & treatment trends in hypertension (RECORD): One year interim analysis

Rajadhyaksha,

Reddy,

Singh

et al. 2023

Indian Journal of Medical Research

View full text Add to dashboard Cite

show abstract

Effectiveness of Telmisartan on Blood Pressure Control in Hypertensive Patients in India: A Real-World Retrospective Study from Electronic Medical Records

et al. 2021

View full text Add to dashboard Cite

Introduction: The effectiveness of telmisartan has been reported in Indian clinical trials; however, real-world data are limited. We aimed to provide real-world evidence regarding the effectiveness of telmisartan as monotherapy or in combination with other antihypertensive drugs (AHDs) in Indian patients with essential hypertension. Methods: Electronic medical record data of adult patients diagnosed with essential hypertension (C 140/90 mmHg) and who were prescribed telmisartan as mono-or add-on therapy were retrospectively analyzed. Patients were classified according to the number of AHD classes prescribed on initiating telmisartan. Change in systolic and diastolic blood pressure (SBP and DBP) after a month of treatment and the proportion of patients who achieved treatment goals according to the 2018 European Society of Cardiology/European Society of Hypertension guidelines were evaluated. Results: A majority (90.6%) of the 1304 patients included in the study were on telmisartan monotherapy or telmisartan ? 1 AHD. The mean (95% confidence interval [CI]) change in the telmisartan monotherapy group was SBP (-13.3 [-14.6, -12.0] mmHg) and DBP (-7.2 [-7.9, -6.5] mmHg), and the mean (95% CI) change in the telmisartan ? 1 AHD group was SBP (-10.8 [-13.1, -8.5] mmHg) and DBP (-6.5 [-7.7, -5.3] mmHg) (P \ 0.001 for all). SBP and DBP goals were achieved by 35.9% and 47.3% of patients on telmisartan monotherapy and by 35.9% and 46.8% of patients on telmisartan ? 1 AHD. Among patients with comorbid diabetes, the mean (95% CI) change in the telmisartan monotherapy group was SBP (-13.3 [-15.0, -11.6] mmHg) and DBP (-7.3 [-8.2, -6.5] mmHg), and the mean (95% CI) change Suyog Mehta was an employee of Dr. Reddy's Laboratories when the study was conducted

show abstract

Effect of Losartan on Different Biochemical Parameters in Essential Hypertensive Patients

Salve

Khanwelkar

Salve

et al. 2019

Biomed. Pharmacol. J.

View full text Add to dashboard Cite

The renin–angiotensin system (RAS) provides the most powerful regulation of blood pressure and angiotensin II is the primary mediator in this system. The binding of angiotensin II to AT1 receptors produces a number of potentially harmful effects that include increase in blood pressure, progression of atherosclerosis, myocardial and vascular hypertrophy. Losartan was the first ARB and found to reduce the risk of stroke, new onset of diabetes and to have a proven benefit in stroke. The present study was designed to evaluate the effect of losartan on different biochemical parameters viz; blood sugar, lipid profile, uric acid and serum electrolytes. 29 newly diagnosed patients of either gender with essential hypertension were included in the study. Baseline readings of lipid profile, serum electrolytes, fasting blood sugar and uric acid were recorded before starting losartan monotherapy and were repeated after six months. After comparing the means, it was revealed that there was a significant increase in HDL cholesterol and a significant decrease in serum uric acid levels after six months of losartan therapy. No significant difference was found in blood sugar and electrolyte levels. These findings suggest that losartan can be an attractive option for the treatment of hypertension and for metabolic syndrome.

show abstract

Effect of telmisartan on blood pressure in patients of type 2 diabetes with or without complications

Cited by 6 publications

References 27 publications

The Indian registry on current patient profiles & treatment trends in hypertension (RECORD): One year interim analysis

The Indian registry on current patient profiles & treatment trends in hypertension (RECORD): One year interim analysis

Effectiveness of Telmisartan on Blood Pressure Control in Hypertensive Patients in India: A Real-World Retrospective Study from Electronic Medical Records

Effect of Losartan on Different Biochemical Parameters in Essential Hypertensive Patients

Contact Info

Product

Resources

About